An observational study in Epilepsy and Glioma, sponsored by University College, London. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University College, London · Observational
Gliomas are the most common and deadliest primary brain tumours in children and adults. Many people with glioma also develop epilepsy, which can be difficult to treat. Research suggests that inflammation in the brain and shared disease pathways may contribute to both glioma and epilepsy. Seizure-related electrical activity may also promote tumour growth and spread.
This study aims to investigate the relationship between blood-brain barrier (BBB) dysfunction, glioma and epilepsy. The BBB normally protects the brain by regulating the movement of substances from the blood into brain tissue. Increased leakage across the BBB may indicate inflammation and may contribute to changes in brain structure and function.
Using a recently developed brain imaging technique, the study will measure BBB leakage in people with glioma, including those with and without tumour-related epilepsy, and in control participants without glioma or epilepsy. The researchers will compare imaging findings between these groups to investigate whether BBB leakage is associated with glioma and epilepsy, and whether it may be linked to structural changes in the brain.
The study will also examine whether the extent of BBB leakage is associated with tumour subtype and grade, and whether this imaging technique could help identify and characterise brain tumours. Finally, the researchers will compare the new imaging technique with conventional contrast-enhanced magnetic resonance imaging (MRI) to assess its ability to detect subtle BBB leakage.
The findings may improve understanding of the relationship between BBB dysfunction, glioma and epilepsy, and help establish the potential value of advanced brain imaging in the diagnosis and assessment of gliomas.
1,848 studies on the registry are indexed under Epilepsy; 422 are open to participants now.
This study's planned enrollment of 56 is below the median of 112 across 540 observational studies indexed under Epilepsy.
Browse Epilepsy studies →University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study will include adults with glioma located in the frontal or temporal regions of the brain, with or without tumour-related epilepsy, and healthy control participants without glioma or epilepsy. The planned main study groups comprise 19 participants with glioma and epilepsy, 19 participants with glioma without epilepsy, and 18 healthy controls. Patients will be identified through the neuro-oncology clinic at Barts Health NHS Trust and approached by their treating consultants. Healthy controls will be recruited from existing volunteer pools at participating centres and through interested friends or relatives of patients who contact the research team directly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants with glioma and tumour-related epilepsy.
participants with glioma who do not have epilepsy.
participants without glioma or epilepsy
Differences in inflammatory markers in people with glioma and healthy controls, as well as between people with glioma with and without epilepsy.
inflammatory markers will be defined as blood brain barrier leakage using filter exchange imaging
Time frame: baseline
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.